To go in a different area for a minute, in Bill C-8, some of the issues that I believe have been raised to you, as a minister—and I'm sure to all of us—are with regard to the generic pharmaceutical companies. The word that is in the bill with respect to “distinctiveness” could undermine or eliminate existing case law to the detriment of pharmacists, patients, and generic pharmaceutical attendants. It has to do with the trademark.
I understand that the industry has been in touch with the minister. I wonder if you have any suggestions that could remedy some of those problems before Bill C-8 is finalized.